Pipeline

Phase I trial successfully completed:

VPM1002: prophylactic Tuberculosis vaccine based on live recombinant M. bovis BCG (rBCGΔureC-Hly) producing lysteriolysin for improved antigen presentation

Phase I/II trial successfully completed:

VPM4001: allogeneic therapeutic Prostate Cancer vaccine based on irradiated transfected LNCaP cells, producing IL-2 and IFN-y. 

Preclinical projects: 

VPM5001: Soluferon^®, a second generation ß-interferon for treatment for Multiple Sclerosis has a high potential to be developed for treatment of viral infections

VPM2001: prophylactic vaccine against Human Cytomegalo Virus (HCMV) using HCMV “dense bodies” as antigens

Unless otherwise indicated, all trademarks are owned by Vakzine Projekt Management GmbH or licensed for its use.